-  INCLUSION CRITERIA:

          -  Histologically or cytologically confirmed stage II or stage III (AJCC 8th edition)
             oropharyngeal squamous cell carcinoma that has not been treated.

          -  HPV16+ tumor and HLA-A 02:01+ HLA type (HLA-A 02 is also acceptable for determination
             of eligibility).

          -  Measurable disease by RECIST 1.1 criteria.

          -  Patient age 18 and older. Because no dosing or adverse event data are currently
             available on the use of E7 TCR T Cells in patients <18 years of age, children are
             excluded from this study. This reflects the age range of patients with the disease
             being studied.

          -  ECOG performance status 0 or 1.

          -  Women of child-bearing potential must have a negative pregnancy test because E7 TCR T
             Cells have unknown potential for teratogenic or abortifacient effects. Women of
             child-bearing potential are defined as all women who are not post-menopausal or who
             have not had a hysterectomy. Postmenopausal will be defined as women over the age of
             55 who have not had a menstrual period in at least 1 year.

          -  The effects of E7 TCR T Cells on the developing human fetus are unknown. For this
             reason and because the chemotherapy agents used in this trial are known to be
             teratogenic, women of child-bearing potential and men must agree to use adequate
             contraception (intrauterine device, hormonal or barrier method of birth control;
             abstinence; tubal ligation or vasectomy) prior to study entry and for four months
             after treatment. Should a woman become pregnant or suspect she is pregnant while she
             or her partner is participating in this study, she should inform her treating
             physician immediately.

          -  Seronegative for HIV antibody. The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive can
             have decreased immune-competence and thus be less responsive to the experimental
             treatment.

          -  Seronegative for hepatitis B antigen and hepatitis C antibody. If hepatitis C antibody
             test is positive, then the patient must be tested for the presence of antigen by
             RT-PCR and be HCV RNA negative.

          -  Must be willing to participate in Gene Therapy Long Term Followup Protocol, which will
             follow patients for up to 15 years per Food and Drug Administration (FDA)
             requirements.

          -  Patients must have organ and marrow function as defined below:

               -  leukocytes- greater than or equal to 3,000/mcL

               -  absolute neutrophil count- greater than or equal to 1,500/mcL

               -  platelets- greater than or equal to 100,000/mcL

               -  hemoglobin- greater than or equal to 9.0 g/dL

               -  total bilirubin- within normal institutional limits except in patients with
                  Gilbert s Syndrome who must have a total bilirubin < 3.0 mg/dL

               -  AST(SGOT)/ALT(SGPT)- Serum ALT/AST < 2.5 times ULN

               -  creatinine clearance- Calculated creatinine clearance (CrCl) >50mL/min/1.73m(2)
                  for patients with creatinine levels above institutional normal (by the Chronic
                  Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents.

          -  History of severe allergic reactions attributed to compounds of similar chemical or
             biologic composition to agents used in study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations at the time of treatment that
             would limit compliance with study requirements.

          -  There is an unknown but potential risk for adverse events in nursing infants secondary
             to treatment of the mother with E7 TCR T Cells. For this reason, women may not
             breastfeed while receiving study treatment and for one year after the study treatment
             ends. These potential risks may also apply to other agents used in this study.

          -  Patients with any form of systemic immunodeficiency, including acquired deficiency
             such as HIV or primary immunodeficiency such as Severe Combined Immunodeficiency
             Disease, are ineligible. The experimental treatment being evaluated in this protocol
             depends on an intact immune system. Patients who have decreased immune competence may
             be less responsive to the treatment.

          -  Current use of immunosuppressive medication, EXCEPT for the following:

               -  Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,
                  intra-articular injection);

               -  Systemic corticosteroids at physiologic doses less than equal to 10 mg/day of
                  prednisone or equivalent;

               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                  premedication)

          -  Patients with autoimmune diseases such as Crohn s disease, ulcerative colitis,
             rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus
             erythematosus. Hypothyroidism, vitiligo and other minor autoimmune disorders are not
             exclusionary.

          -  Patients with a second active invasive cancer are not eligible if it may confound
             assessment of response to the current therapy.

          -  Patients who do not have a local physician to provide standard therapy post treatment.